DSIP vs. Lixisenatide

Category

Research other

Metabolic

CAS no.

62568-57-4

320367-13-3

Molecular weight

848.81 g/mol

4858.5 g/mol

Half-life

0.1 h

3 h

Sequence

DSIP

DSIP was described in 1977 by the Schoenenberger-Monnier group in Basel as a blood-borne substance reported to induce EEG changes similar to delta sleep in animal models. The exact mechanism remains undefined to this day: no defined receptor, proposed modulation of opioid, GABAergic and glutamatergic systems. Most mechanistic findings stem from preclinical studies of the 1980s and 1990s and were later subjected to contested replication attempts.

Lixisenatide

Lixisenatide is a 44-amino-acid peptide based on exendin-4 (see exenatide) with six additional lysine residues at the C-terminus. This modification increases stability against DPP-4 degradation. The short half-life (~3 hours) and plasma peak around mealtime explain the predominantly prandial effect — stronger postprandial glucose action, weaker fasting glucose effect than weekly GLP-1 RAs.

Highest evidence

Studies

4

5

of which in humans

1

5

Effects recorded

3

3

Open conflicts

1

1

Documented adverse events

1

1